ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 104 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,256,230 | -36.1% | 4,220,048 | 0.0% | 2.22% | +1.4% |
| Q2 2023 | $31,692,560 | +66.2% | 4,220,048 | 0.0% | 2.19% | +65.3% |
| Q1 2023 | $19,074,617 | +40006.4% | 4,220,048 | 0.0% | 1.32% | -75.8% |
| Q4 2022 | $47,560 | -99.9% | 4,220,048 | 0.0% | 5.48% | +22.8% |
| Q3 2022 | $40,386,000 | +18.3% | 4,220,048 | 0.0% | 4.46% | +30.1% |
| Q2 2022 | $34,140,000 | -52.1% | 4,220,048 | 0.0% | 3.43% | -30.2% |
| Q1 2022 | $71,319,000 | -21.4% | 4,220,048 | 0.0% | 4.91% | -10.2% |
| Q4 2021 | $90,689,000 | -70.9% | 4,220,048 | 0.0% | 5.47% | -60.9% |
| Q3 2021 | $311,693,000 | +35.1% | 4,220,048 | 0.0% | 14.00% | +40.1% |
| Q2 2021 | $230,752,000 | -25.8% | 4,220,048 | 0.0% | 9.99% | -8.7% |
| Q1 2021 | $311,186,000 | -14.5% | 4,220,048 | 0.0% | 10.94% | -32.6% |
| Q4 2020 | $363,768,000 | +128.4% | 4,220,048 | 0.0% | 16.23% | +76.4% |
| Q3 2020 | $159,265,000 | – | 4,220,048 | – | 9.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |